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Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3)
, following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.
NAME

Rucaparib (Rubraca)
APPROVED FOR
Ovarian cancer
TYPE
Small molecule
MOLECULAR TARGETS
PARP-1 (+ PARP-2 and PARP-3)
CELLULAR TARGETS
Cancer cells with BRCA1 or BRCA2 mutations
EFFECTS ON TARGETS
Inhibition of PARP-1 (and other nuclear PARPs) leads to the accumulation of DNA damage by impairing single-strand DNA break repair (SSBR) and trapping PARP-1 at single-strand break sites, leading to inhibition of DNA replication. Cells with mutations in the BRCA1 or BRCA2 genes, which encode key homologous recombination (HR) proteins, are impaired in their ability to repair these types of DNA damage and restore replication, resulting in cell death. Inhibition of nuclear PARPs can also disrupt normal DNA replication processes, chromatin remodeling, and gene expression, as well as inflammatory and hypoxic responses. 
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